Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188. https://doi.org/10.1093/eurheartj/ehz455

Article  PubMed  Google Scholar 

Nurmohamed NS, Navar AM, Kastelein JJP (2021) New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B: JACC focus seminar 1/4. J Am Coll Cardiol 77(12):1564–1575. https://doi.org/10.1016/j.jacc.2020.11.079

Article  CAS  PubMed  Google Scholar 

Boren J, Chapman MJ, Krauss RM et al (2020) Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 41(24):2313–2330. https://doi.org/10.1093/eurheartj/ehz962

Article  CAS  PubMed Central  PubMed  Google Scholar 

Ference BA, Kastelein JJP, Catapano AL (2020) Lipids and lipoproteins in 2020. JAMA 324(6):595–596. https://doi.org/10.1001/jama.2020.5685

Article  PubMed  Google Scholar 

Timmis A, Vardas P, Townsend N et al (2022) European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 43(8):716–799. https://doi.org/10.1093/eurheartj/ehab892

Article  PubMed  Google Scholar 

Lawler PR, Kotrri G, Koh M et al (2020) Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. Eur Heart J 41(1):86–94. https://doi.org/10.1093/eurheartj/ehz767

Article  PubMed  Google Scholar 

Vallejo-Vaz AJ, Fayyad R, Boekholdt SM et al (2018) Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT Trial. Circulation 138(8):770–781. https://doi.org/10.1161/CIRCULATIONAHA.117.032318

Article  CAS  PubMed  Google Scholar 

Hoogeveen RC, Ballantyne CM (2021) Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation. Clin Chem 67(1):143–153. https://doi.org/10.1093/clinchem/hvaa252

Article  PubMed  Google Scholar 

Tokgozoglu L, Libby P (2022) The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J 43(34):3198–3208. https://doi.org/10.1093/eurheartj/ehab841

Article  CAS  PubMed Central  Google Scholar 

Raposeiras-Roubin S, Rossello X, Oliva B et al (2021) Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol 77(24):3031–3041. https://doi.org/10.1016/j.jacc.2021.04.059

Article  CAS  PubMed Central  PubMed  Google Scholar 

Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S (2019) Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab 21(2):366–371. https://doi.org/10.1111/dom.13537

Article  CAS  PubMed  Google Scholar 

Zhao Y, Xiang P, Coll B, Lopez JAG, Wong ND (2021) Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease. J Diabetes Complications 35(3):107767. https://doi.org/10.1016/j.jdiacomp.2020.107767

Article  CAS  PubMed  Google Scholar 

Vallejo-Vaz AJ, Corral P, Schreier L, Ray KK (2020) Triglycerides and residual risk. Curr Opin Endocrinol Diabetes Obes 27(2):95–103. https://doi.org/10.1097/MED.0000000000000530

Article  CAS  PubMed  Google Scholar 

Chait A, Ginsberg HN, Vaisar T, Heinecke JW, Goldberg IJ, Bornfeldt KE (2020) Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes 69(4):508–516. https://doi.org/10.2337/dbi19-0007

Article  CAS  PubMed Central  PubMed  Google Scholar 

Fan W, Philip S, Granowitz C, Toth PP, Wong ND (2019) Residual hypertriglyceridemia and estimated atherosclerotic cardiovascular disease risk by statin use in U.S. adults with diabetes: National Health and Nutrition Examination Survey 2007-2014. Diabetes Care 42(12):2307–2314. https://doi.org/10.2337/dc19-050110.2337/dc19-0501

Article  PubMed  Google Scholar 

Chapman MJ, Zamorano JL, Parhofer KG (2022) Reducing residual cardiovascular risk in Europe: therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Pharmacol Ther 237:108172. https://doi.org/10.1016/j.pharmthera.2022.108172

Article  CAS  PubMed  Google Scholar 

Ginsberg HN, Packard CJ, Chapman MJ et al (2021) Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J 42(47):4791–4806. https://doi.org/10.1093/eurheartj/ehab551

Article  CAS  PubMed Central  PubMed  Google Scholar 

Ference BA, Kastelein JJP, Ray KK et al (2019) Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA 321(4):364–373. https://doi.org/10.1001/jama.2018.20045

Article  CAS  PubMed Central  PubMed  Google Scholar 

Hegele RA, Tsimikas S (2019) Lipid-lowering agents. Circ Res 124(3):386–404. https://doi.org/10.1161/CIRCRESAHA.118.313171

Article  CAS  PubMed  Google Scholar 

Frick MH, Elo O, Haapa K et al (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317(20):1237–1245. https://doi.org/10.1056/NEJM198711123172001

Article  CAS  PubMed  Google Scholar 

Rubins HB, Robins SJ, Collins D et al (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341(6):410–418. https://doi.org/10.1056/NEJM199908053410604

Article  CAS  PubMed  Google Scholar 

Keech A, Simes RJ, Barter P et al (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500):1849–1861. https://doi.org/10.1016/S0140-6736(05)67667-2

Article  CAS  PubMed  Google Scholar 

Das Pradhan A, Glynn RJ, Fruchart JC et al (2022) Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 387(21):1923–1934. https://doi.org/10.1056/NEJMoa2210645

Article  PubMed  Google Scholar 

Boren J, Taskinen MR, Bjornson E, Packard CJ (2022) Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nat Rev Cardiol 19(9):577–592. https://doi.org/10.1038/s41569-022-00676-y

Article  CAS  PubMed  Google Scholar 

Nordestgaard BG (2016) Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res 118(4):547–563. https://doi.org/10.1161/CIRCRESAHA.115.306249

Article  CAS  PubMed  Google Scholar 

Packard CJ, Boren J, Taskinen MR (2020) Causes and consequences of hypertriglyceridemia. Front Endocrinol 11:252. https://doi.org/10.3389/fendo.2020.00252

Article  Google Scholar 

Boren J, Packard CJ, Taskinen MR (2020) The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol 11:474. https://doi.org/10.3389/fendo.2020.00474

Article  Google Scholar 

Wen Y, Chen YQ, Konrad RJ (2022) The regulation of triacylglycerol metabolism and lipoprotein lipase activity. Adv Biol 6(10):e2200093. https://doi.org/10.1002/adbi.202200093

Article  CAS  Google Scholar 

Xiao C, Stahel P, Carreiro AL, Buhman KK, Lewis GF (2018) Recent advances in triacylglycerol mobilization by the gut. Trends Endocrinol Metab 29(3):151–163. https://doi.org/10.1016/j.tem.2017.12.001

Article  CAS  PubMed  Google Scholar 

Mulvihill EE (2018) Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. Curr Opin Lipidol 29(2):95–103. https://doi.org/10.1097/MOL.0000000000000495

Article  CAS  PubMed Central  PubMed  Google Scholar 

Tall AR (2017) Increasing lipolysis and reducing atherosclerosis. New Engl J Med 377(3):280–283. https://doi.org/10.1056/NEJMe1706907

Article  PubMed  Google Scholar 

Khera AV, Won HH, Peloso GM et al (2017) Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease. JAMA 317(9):937–946. https://doi.org/10.1001/jama.2017.0972

Article  CAS  PubMed Central  PubMed  Google Scholar 

Gaudet D, Karwatowska-Prokopczuk E, Baum SJ et al (2020) Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J 41(40):3936–3945. https://doi.org/10.1093/eurheartj/ehaa689

Article  CAS  PubMed Central  PubMed